Organon & Co | OGN - Actif À Court Terme





Actif À Court Terme Changement Date
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Celltrion KRW 470.6B 5.07T 2025-12
Cspc Pharmaceutical CNY 22.25B 359.48M 2025-12
Deva Holding AS TRY 9.13B 1.61B 2023-09
Dianthus Therapeutics USD 1.12B 710.47M 2026-03
Divis Laboratories Ltd INR 110.96B 12.53B 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
Glaxosmithkline GBP 23.59B 390.44M 2025-12
Kangmei Pharma CNY 6.8B 225.83M 2026-03
Knight Therapeutics CAD 394.84M 5.86M 2025-12
Laboratorios Farma EUR 509.33M 128.63M 2023-12
Malin Corporation EUR 62.6M 26.7M 2024-12
Medical Developments International AUD 33.75M 1.79M 2025-12
Merck USD 35.02B 8.5B 2026-03
Neuren Pharmaceuticals AUD 332.23M 11.98M 2025-12
Novartis USD 30.46B 2.26B 2025-12
Organigram Holdings CAD 256.54M 28.35M 2025-12
Organon & Co USD 4.93B 580M 2026-03
Ovoca Bio EUR 1.56M 3.39M 2025-06
Pharma Mar EUR 273.45M 9.96M 2026-03
Qiagen NV USD 2B 535.87M 2025-12
Sartorius EUR 1.92B 157.2M 2026-03
Sino Biopharmaceutical CNY 33.82B 9.13B 2025-06
Tilray USD 729.32M 28.18M 2025-09
Zealand Pharma A/S 15.67B 950.94M 2025-12